Connect your AI

Upstream Bio, Inc. UPB Proceeds from maturities of short-term investments

Proceeds from maturities of short-term investments at other companies

Avalo TherapeuticsAVTX

——

Other financials

Income statement

Revenue$1.0M+82.7%

Operating income-$43.6M-36.2%

Net income-$40.6M-48.8%

EPS (diluted)-$0.75-47.1%

Balance sheet

Cash & equivalents$96.7M+35.6%

Total debt$1.1M-34.5%

Total equity$304.0M-31.8%

Total assets$318.1M-30.3%

Cash flow

Operating cash flow-$47.9M-16.2%

CapEx$54.0K-70.8%

Free cash flow-$30.7M-55.0%

Valuation

Market cap$346.11M-40.9%

Enterprise value$250.5M-51.4%

P/S104.2×-151×

Profitability

Operating margin-5,176.5%+1,764pp

Net margin-4,719%+2,752pp

Returns & leverage

Return on equity-41.8%—

Debt / equity0×0.0×

Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s proceeds from maturities of short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Upstream Bio, Inc.'s proceeds from maturities of short-term investments?: Upstream Bio, Inc. (UPB) reported proceeds from maturities of short-term investments of $56.82M in Q1 2026.
How has Upstream Bio, Inc.'s proceeds from maturities of short-term investments changed year-over-year?: Upstream Bio, Inc.'s proceeds from maturities of short-term investments increased by 7.9% year-over-year, from $52.68M to $56.82M.